MA26914A1 - Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale - Google Patents

Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale

Info

Publication number: MA26914A1
Authority: MA; Morocco
Prior art keywords: treatment; cell growth; abnormal cell; substituted bicyclic; bicyclic derivatives
Prior art date: 2000-06-22

Application number

MA26954A

Other languages

English (en)

Inventor

Charles Kath John

Kumar Bhattacharya Samit

Morris Joel

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-22

Filing date

2002-12-16

Publication date

2004-12-20

2002-12-16 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-12-20 Publication of MA26914A1 publication Critical patent/MA26914A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Steroid Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines Containing Plant Substances (AREA)

MA26954A 2000-06-22 2002-12-16 Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale MA26914A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US21313600P	2000-06-22	2000-06-22

Publications (1)

Publication Number	Publication Date
MA26914A1 true MA26914A1 (fr)	2004-12-20

Family

ID=22793862

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26954A MA26914A1 (fr)	2000-06-22	2002-12-16	Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale

Country Status (42)

Country	Link
US (2)	US6890924B2 (fr)
EP (1)	EP1292591B1 (fr)
JP (1)	JP4044839B2 (fr)
KR (1)	KR100545537B1 (fr)
CN (3)	CN101348467A (fr)
AP (1)	AP2001002192A0 (fr)
AR (1)	AR032353A1 (fr)
AT (1)	ATE288431T1 (fr)
AU (1)	AU2001264159A1 (fr)
BG (1)	BG107269A (fr)
BR (1)	BR0111548A (fr)
CA (1)	CA2413424C (fr)
CZ (1)	CZ20023951A3 (fr)
DE (1)	DE60108754T2 (fr)
DK (1)	DK1292591T3 (fr)
DZ (1)	DZ3407A1 (fr)
EA (1)	EA005525B1 (fr)
EC (1)	ECSP024393A (fr)
EE (1)	EE200200710A (fr)
ES (1)	ES2236240T3 (fr)
GE (1)	GEP20063831B (fr)
HR (1)	HRP20021005A2 (fr)
HU (1)	HUP0301120A2 (fr)
IL (1)	IL152985A0 (fr)
IS (1)	IS6616A (fr)
MA (1)	MA26914A1 (fr)
MX (1)	MXPA02012870A (fr)
MY (1)	MY127181A (fr)
NO (1)	NO20026166L (fr)
NZ (1)	NZ522568A (fr)
OA (1)	OA12291A (fr)
PA (1)	PA8520301A1 (fr)
PE (1)	PE20020257A1 (fr)
PL (1)	PL359557A1 (fr)
PT (1)	PT1292591E (fr)
SK (1)	SK17102002A3 (fr)
SV (1)	SV2002000504A (fr)
TN (1)	TNSN01091A1 (fr)
UA (1)	UA73990C2 (fr)
WO (1)	WO2001098277A2 (fr)
YU (1)	YU95102A (fr)
ZA (1)	ZA200210231B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7772432B2 (en) *	1991-09-19	2010-08-10	Astrazeneca Ab	Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9800569D0 (en) *	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
WO2000020402A1 (fr)	1998-10-01	2000-04-13	Astrazeneca Ab	Composes chimiques
JP4044839B2 (ja) *	2000-06-22	2008-02-06	ファイザー・プロダクツ・インク	異常細胞増殖を治療するための置換２環式誘導体
JP4285996B2 (ja) *	2001-02-21	2009-06-24	田辺三菱製薬株式会社	キナゾリン誘導体
US20030144308A1 (en) *	2001-09-24	2003-07-31	Bauer Paul H.	Fructose 1,6-bisphosphatase inhibitors
CA2462149C (fr) *	2001-11-30	2010-06-22	Pfizer Products Inc.	Procedes de preparation de derives bicycliques substitues utilise pour traiter la croissance cellulaire anormale
AU2002339687A1 (en) *	2001-12-12	2003-06-23	Pfizer Products Inc.	Quinazoline derivatives for the treatement of abnormal cell growth
HRP20040530A2 (en) *	2001-12-12	2004-10-31	Pfizer Prod Inc	Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP4703183B2 (ja)	2002-07-15	2011-06-15	シンフォニーエボルーション，インク．	受容体型キナーゼモジュレーターおよびその使用方法
US7488823B2 (en)	2003-11-10	2009-02-10	Array Biopharma, Inc.	Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP4611745B2 (ja)	2002-11-20	2011-01-12	アレイバイオファーマ、インコーポレイテッド	ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン
RU2005119172A (ru) *	2002-12-18	2006-01-20	Пфайзер Продактс Инк. (Us)	Производные 4-анилинхиназолина для лечения патологического роста клеток
RU2005122659A (ru) *	2002-12-19	2006-01-20	Пфайзер Продактс Инк. (Us)	Комплексы е-2-метокси-n-(3-{4-[3-метил-4-(6-метилпиридин-3-илокси) фениламино] хиназолин-6-ил} аллил) ацетамида, способ получения и применения указанных комплексов
RS20050652A (sr) *	2003-04-09	2007-11-15	Pfizer Products Inc.,	Postupak za izradu derivata n- (((piridiniloksi)-fenilamino) kvinazolinil)-alil)acetamida i izvedenih jedinjenja kao i međuproizvodi ovih postupaka i postupci za izradu ovih međuproizvoda
EP1636195A1 (fr) *	2003-05-27	2006-03-22	Pfizer Products Inc.	Quinazolines et pyrido 3,4-d] pyrimidines utilises comme inhibiteurs de recepteurs tyrosine kinase
NZ544472A (en)	2003-07-03	2009-04-30	Myriad Genetics Inc	Compounds and therapeutical use thereof
US8309562B2 (en)	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
WO2006074147A2 (fr)	2005-01-03	2006-07-13	Myriad Genetics, Inc.	Composes et utilisation therapeutique associee
CA2529777A1 (fr) *	2003-07-15	2005-01-27	National Research Council Of Canada	Analogues cycliques de l'hormone parathyroide humaine destines au traitement d'etats caracterises par l'hyperproliferation des cellules de la peau
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
NZ545459A (en) *	2003-08-14	2009-12-24	Array Biopharma Inc	Quinazoline analogs as receptor tyrosine kinase inhibitors
SG135193A1 (en) *	2003-08-18	2007-09-28	Pfizer Prod Inc	Dosing schedule for erbb2 anticancer agents
US7569577B2 (en)	2003-09-16	2009-08-04	Astrazeneca Ab	Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
ES2651730T3 (es) *	2003-09-26	2018-01-29	Exelixis, Inc.	Moduladores c-Met y métodos de uso
JP2007510708A (ja) *	2003-11-06	2007-04-26	ファイザー・プロダクツ・インク	癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
EP1713781B1 (fr)	2004-02-03	2008-11-05	AstraZeneca AB	Derives de quinazoline
US20050192298A1 (en) *	2004-02-27	2005-09-01	Pfizer Inc	Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
MX2007000610A (es)	2004-07-16	2007-03-07	Pfizer Prod Inc	Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
EP1792898A1 (fr) *	2004-09-01	2007-06-06	Mitsubishi Pharma Corporation	Régulateur de la fonction de chaperon moléculaire
KR100735639B1 (ko)	2004-12-29	2007-07-04	한미약품 주식회사	암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
WO2006071079A1 (fr) *	2004-12-29	2006-07-06	Hanmi Pharm. Co., Ltd.	Dérivés de quinazoline employés dans l'inhibition de la croissance des cellules cancéreuses et méthodes de synthèse desdits dérivés
US8258145B2 (en)	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
CA2763671A1 (fr)	2005-04-26	2006-11-02	Pfizer Inc.	Anticorps de la p-cadherine
CA2610491A1 (fr) *	2005-06-03	2006-12-07	Pfizer Products Inc.	Derives bicycliques pour le traitement de croissance cellulaire anormale
JP2008542354A (ja) *	2005-06-03	2008-11-27	ファイザー・プロダクツ・インク	癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
MY164457A (en)	2005-09-07	2017-12-15	Amgen Fremont Inc	Human monoclonal antibodies to activin receptor-like kinase-1
DE602006009968D1 (de)	2005-11-15	2009-12-03	Array Biopharma Inc	N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
GB0526552D0 (en) *	2005-12-29	2006-02-08	Morvus Technology Ltd	New use
EP2258700A1 (fr)	2006-05-09	2010-12-08	Pfizer Products Inc.	Dérivés d'acides aminés cycloalkyles et compositions pharmaceutiques les contenant
WO2008002039A1 (fr) *	2006-06-28	2008-01-03	Hanmi Pharm. Co., Ltd.	Dérivés de quinazoline destinés à inhiber le développement de cellules cancéreuses
US7547781B2 (en)	2006-09-11	2009-06-16	Curis, Inc.	Quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2007296744A1 (en) *	2006-09-11	2008-03-20	Curis, Inc.	Multi-functional small molecules as anti-proliferative agents
EP2061773A4 (fr) *	2006-09-11	2011-01-19	Curis Inc	Inhibiteurs d'egfr à base de quinazoline contenant un fragment de liaison au zinc
EP1921070A1 (fr)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
CN101611041A (zh)	2006-12-12	2009-12-23	武田药品工业株式会社	稠合杂环化合物
WO2008095847A1 (fr)	2007-02-06	2008-08-14	Boehringer Ingelheim International Gmbh	Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation
ES2529790T3 (es)	2007-04-13	2015-02-25	Dana-Farber Cancer Institute, Inc.	Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
WO2009098061A1 (fr)	2008-02-07	2009-08-13	Boehringer Ingelheim International Gmbh	Hétérocycles spirocycliques, médicaments contenant ces composés, leur utilisation et procédé pour les produire
WO2009113560A1 (fr)	2008-03-12	2009-09-17	武田薬品工業株式会社	Composé hétérocyclique fusionné
US8426430B2 (en) *	2008-06-30	2013-04-23	Hutchison Medipharma Enterprises Limited	Quinazoline derivatives
US8648191B2 (en)	2008-08-08	2014-02-11	Boehringer Ingelheim International Gmbh	Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CA2758030C (fr)	2009-01-16	2019-01-08	Exelixis, Inc.	Sel de malate de n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide et formes cristallines de celui-ci pour le traitement du cancer
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP2013503846A (ja)	2009-09-01	2013-02-04	ファイザー・インク	ベンズイミダゾール誘導体
WO2011153050A1 (fr)	2010-06-02	2011-12-08	The Trustees Of The University Of Pennsylvania	Méthodes et utilisation de composés qui se lient au complexe du récepteur her2/neu
US8993634B2 (en)	2010-06-02	2015-03-31	The Trustees Of The University Of Pennsylvania	Methods and use of compounds that bind to Her2/neu receptor complex
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
EP2630134B9 (fr)	2010-10-20	2018-04-18	Pfizer Inc	Dérivés de 2-pyridine comme modulateurs du récepteur smoothened
PH12014500638A1 (en)	2011-09-22	2017-08-09	Pfizer	Pyrrolopyrimidine and purine derivatives
CN102872018B (zh) *	2012-10-23	2015-07-15	广州市恒诺康医药科技有限公司	酪氨酸激酶不可逆抑制剂及其制备方法和用途
US9468681B2 (en)	2013-03-01	2016-10-18	California Institute Of Technology	Targeted nanoparticles
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (fr)	2014-04-10	2015-10-15	Pfizer Inc.	Dérivés de dihydropyrrolopyrimidine
CR20160497A (es)	2014-04-30	2016-12-20	Pfizer	Derivados de diheterociclo enlazado a cicloalquilo
KR101589632B1 (ko)	2014-06-03	2016-02-01	한국과학기술연구원	항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
WO2016001789A1 (fr)	2014-06-30	2016-01-07	Pfizer Inc.	Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
CN107922609B (zh)	2015-07-01	2020-04-24	加州理工学院	基于阳离子粘酸聚合物的递送系统
WO2017009751A1 (fr)	2015-07-15	2017-01-19	Pfizer Inc.	Dérivés de pyrimidine
JP6791979B2 (ja)	2016-03-01	2020-11-25	シャンハイファーマシューティカルズホールディングカンパニー，リミティド	含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
JP7483193B2 (ja)	2018-06-13	2024-05-15	カリフォルニア・インスティテュート・オブ・テクノロジー	血脳バリアを越えるためのナノ粒子とそれを用いた治療法
RS65413B1 (sr)	2018-09-18	2024-05-31	Hoffmann La Roche	Derivati hinazolina kao antitumorski agensi
CN118715216A (zh) *	2022-03-28	2024-09-27	江苏恒瑞医药股份有限公司	含氮杂环类化合物、其制备方法及其在医药上的应用
WO2025067396A1 (fr) *	2023-09-27	2025-04-03	江苏恒瑞医药股份有限公司	Sel pharmaceutiquement acceptable et forme cristalline d'un dérivé de quinazoline, et leur utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW321649B (fr) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
US6225318B1 (en)	1996-10-17	2001-05-01	Pfizer Inc	4-aminoquinazolone derivatives
ZA986732B (en) *	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
BR9914326A (pt)	1998-10-08	2001-06-26	Astrazeneca Ab	Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou de redução da permeabilidade vascular em animais de sangue quente em necessidade de um tal tratamento
UA71945C2 (en) *	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) *	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
JP4044839B2 (ja) *	2000-06-22	2008-02-06	ファイザー・プロダクツ・インク	異常細胞増殖を治療するための置換２環式誘導体

2001
- 2001-06-14 JP JP2002504233A patent/JP4044839B2/ja not_active Expired - Fee Related
- 2001-06-14 NZ NZ522568A patent/NZ522568A/xx unknown
- 2001-06-14 AU AU2001264159A patent/AU2001264159A1/en not_active Abandoned
- 2001-06-14 PL PL01359557A patent/PL359557A1/xx not_active Application Discontinuation
- 2001-06-14 EE EEP200200710A patent/EE200200710A/xx unknown
- 2001-06-14 CA CA002413424A patent/CA2413424C/fr not_active Expired - Fee Related
- 2001-06-14 YU YU95102A patent/YU95102A/sh unknown
- 2001-06-14 KR KR1020027017489A patent/KR100545537B1/ko not_active Expired - Fee Related
- 2001-06-14 UA UA20021210405A patent/UA73990C2/uk unknown
- 2001-06-14 EP EP01938484A patent/EP1292591B1/fr not_active Expired - Lifetime
- 2001-06-14 OA OA1200200382A patent/OA12291A/en unknown
- 2001-06-14 EA EA200201277A patent/EA005525B1/ru not_active IP Right Cessation
- 2001-06-14 MX MXPA02012870A patent/MXPA02012870A/es active IP Right Grant
- 2001-06-14 AP APAP/P/2001/002192A patent/AP2001002192A0/en unknown
- 2001-06-14 DK DK01938484T patent/DK1292591T3/da active
- 2001-06-14 GE GE5023A patent/GEP20063831B/en unknown
- 2001-06-14 PT PT01938484T patent/PT1292591E/pt unknown
- 2001-06-14 AT AT01938484T patent/ATE288431T1/de not_active IP Right Cessation
- 2001-06-14 HU HU0301120A patent/HUP0301120A2/hu unknown
- 2001-06-14 CZ CZ20023951A patent/CZ20023951A3/cs unknown
- 2001-06-14 CN CNA200810144110XA patent/CN101348467A/zh active Pending
- 2001-06-14 IL IL15298501A patent/IL152985A0/xx unknown
- 2001-06-14 ES ES01938484T patent/ES2236240T3/es not_active Expired - Lifetime
- 2001-06-14 DE DE60108754T patent/DE60108754T2/de not_active Expired - Lifetime
- 2001-06-14 CN CNB2004100696071A patent/CN1330640C/zh not_active Expired - Fee Related
- 2001-06-14 DZ DZ013407A patent/DZ3407A1/fr active
- 2001-06-14 CN CN01811470A patent/CN1437594A/zh active Pending
- 2001-06-14 SK SK1710-2002A patent/SK17102002A3/sk unknown
- 2001-06-14 WO PCT/IB2001/001046 patent/WO2001098277A2/fr not_active Ceased
- 2001-06-14 HR HR20021005A patent/HRP20021005A2/xx not_active Application Discontinuation
- 2001-06-14 BR BR0111548-0A patent/BR0111548A/pt not_active IP Right Cessation
- 2001-06-18 US US09/883,752 patent/US6890924B2/en not_active Expired - Fee Related
- 2001-06-20 PA PA20018520301A patent/PA8520301A1/es unknown
- 2001-06-20 MY MYPI20012895 patent/MY127181A/en unknown
- 2001-06-20 PE PE2001000598A patent/PE20020257A1/es not_active Application Discontinuation
- 2001-06-20 AR ARP010102936A patent/AR032353A1/es unknown
- 2001-06-21 TN TNTNSN01091A patent/TNSN01091A1/fr unknown
- 2001-06-21 SV SV2001000504A patent/SV2002000504A/es not_active Application Discontinuation
2002
- 2002-11-12 BG BG107269A patent/BG107269A/bg unknown
- 2002-11-14 IS IS6616A patent/IS6616A/is unknown
- 2002-12-13 EC EC2002004393A patent/ECSP024393A/es unknown
- 2002-12-16 MA MA26954A patent/MA26914A1/fr unknown
- 2002-12-18 ZA ZA200210231A patent/ZA200210231B/en unknown
- 2002-12-20 NO NO20026166A patent/NO20026166L/no unknown
2005
- 2005-03-14 US US11/079,648 patent/US7332493B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PA8520301A1 (es)	2003-06-30
DE60108754T2 (de)	2005-06-23
ECSP024393A (es)	2003-02-06
UA73990C2 (en)	2005-10-17
SV2002000504A (es)	2002-10-24
MY127181A (en)	2006-11-30
PE20020257A1 (es)	2002-04-08
US20050159435A1 (en)	2005-07-21
CZ20023951A3 (cs)	2004-01-14
ES2236240T3 (es)	2005-07-16
HRP20021005A2 (en)	2004-02-29
US6890924B2 (en)	2005-05-10
NZ522568A (en)	2004-12-24
US7332493B2 (en)	2008-02-19
YU95102A (sh)	2005-11-28
BG107269A (bg)	2003-06-30
EA200201277A1 (ru)	2003-06-26
EP1292591B1 (fr)	2005-02-02
IL152985A0 (en)	2003-06-24
JP2004501139A (ja)	2004-01-15
HUP0301120A2 (hu)	2003-08-28
AR032353A1 (es)	2003-11-05
KR100545537B1 (ko)	2006-01-25
CN1576275A (zh)	2005-02-09
CN101348467A (zh)	2009-01-21
PL359557A1 (en)	2004-08-23
AU2001264159A1 (en)	2002-01-02
WO2001098277A2 (fr)	2001-12-27
OA12291A (en)	2004-03-18
TNSN01091A1 (fr)	2005-11-10
BR0111548A (pt)	2003-05-06
EP1292591A2 (fr)	2003-03-19
CN1437594A (zh)	2003-08-20
DE60108754D1 (de)	2005-03-10
NO20026166D0 (no)	2002-12-20
KR20030016303A (ko)	2003-02-26
DZ3407A1 (fr)	2001-12-27
CN1330640C (zh)	2007-08-08
JP4044839B2 (ja)	2008-02-06
EA005525B1 (ru)	2005-04-28
HK1069576A1 (en)	2005-05-27
AP2001002192A0 (en)	2002-12-21
US20020169165A1 (en)	2002-11-14
NO20026166L (no)	2002-12-20
WO2001098277A3 (fr)	2002-06-13
SK17102002A3 (sk)	2004-04-06
CA2413424C (fr)	2007-10-02
MXPA02012870A (es)	2003-05-14
PT1292591E (pt)	2005-06-30
GEP20063831B (en)	2006-05-25
DK1292591T3 (da)	2005-05-30
IS6616A (is)	2002-11-14
CA2413424A1 (fr)	2001-12-27
EE200200710A (et)	2004-06-15
ATE288431T1 (de)	2005-02-15
ZA200210231B (en)	2004-02-12

Publication	Publication Date	Title
MA26914A1 (fr)	2004-12-20	Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale
MA26822A1 (fr)	2004-12-20	Composes pour le traitement d'une ischemie.
MA25823A1 (fr)	2003-07-01	Compositions pour le traitement de l'eau.
DK1112106T3 (da)	2005-12-12	Serotonerge 5HT2-agonister til behandling af glaukom
EP1165110A4 (fr)	2002-08-07	Antagonistes de hmg1 destines au traitement d'etats inflammatoires
DE60135029D1 (de)	2008-09-04	Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
TNSN99236A1 (fr)	2005-11-10	Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2772746B1 (fr)	2000-01-28	Procede de fabrication d'une ceramique apatitique, en particulier pour usage biologique
MA25493A1 (fr)	2002-07-01	Derives de 3(5)-amino-pyrazole, procede pour leur preparation et leur utilisation en tant qu'agents antitumoraux.
MA25411A1 (fr)	2002-04-01	Microorganismes attenues pour le traitement d'infection.
MA25984A1 (fr)	2003-12-31	Procede pour preparation de maleate d'amlodipine.
DZ3014A1 (fr)	2004-03-27	Médicaments pour le traitement de l'hypertension.
NO20012638L (no)	2001-08-06	Blandinger og fremgangsmåter for å kontrollere avsetning av vann-ulöselige ingredienser
MA25847A1 (fr)	2003-07-01	Composition pour le traitement du dysfonctionnement endothelial.
MA28583B1 (fr)	2007-05-02	Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale
EP1448193A4 (fr)	2005-11-23	Composes therapeutiques pour le traitement d'etats dyslipidemiques
EP1161255A4 (fr)	2002-07-17	Procedes et compositions pour le traitement de la dyserection
EP1572129A4 (fr)	2007-03-28	Derives d'amidine pour le traitement des amyloses
NO20013146L (no)	2001-08-20	Middel for behandling av synscellefunksjonsforstyrrelse
FR2800614B1 (fr)	2002-01-04	Composition pour le traitement des infections des voies respiratoires
FR2758465B1 (fr)	1999-04-09	Composition pour le traitement de l'amiante
EP1582209A4 (fr)	2010-02-10	Utilisation d'esters de derives succinate pour le traitement de la demence
ATE230741T1 (de)	2003-01-15	3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
MA26117A1 (fr)	2004-04-01	Nouveau compose pour le traitement de l'impuissance
MA26856A1 (fr)	2004-12-20	Bisindolymaleimides substitues pour l'inhibition de la proliferation de cellules